The Global E-Cigarettes Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the E-Cigarettes market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/e-cigarettes-market-14447

Quick market snapshot
Reported global market-size estimates vary because houses use different scopes (devices only, devices+consumables, or all ENDS). Example baselines: USD ~26–31B in the mid-2020s with divergent long-range forecasts (some firms show very high CAGRs; others show modest growth). Grand View projects ~USD 28.2B (2023) and a very aggressive scenario to ~USD 182.8B by 2030 (wider scope); Mordor reports ~USD 26.1B (2025) with a more moderate CAGR to 2030. Pick the scope you want and I’ll normalise numbers across firms.

Key companies — who’s named repeatedly (with public values / notes where available)
Philip Morris International (PMI) — major global smoke-free business (IQOS heated tobacco + inhalable products). PMI reports its smoke-free business accounted for ~39–42% of total net revenues in 2024; smoke-free product sales were explicitly reported (~USD 4.2B in one quarter/period references). PMI is a major industrial player in reduced-risk nicotine categories.

British American Tobacco (BAT) — leading “new categories” portfolio (Vuse, Glo, Velo). BAT reported revenue from New Categories of ~£3.4 billion (2024) — showing material scale in vapour/heated/modern oral.

SMOORE (Smoore International) — the world’s largest vaping device manufacturer / OEM (many brands source devices from Smoore). Public company filings show 2024 revenue ~RMB 11.75 billion (~USD 1.6B). Smoore is primarily a device/OEM supplier rather than a consumer brand.

RLX Technology (RELX / RLX) — a large China-based vaping brand. Recent company filings / PR show quarterly revenue growth (Q2 2025 RMB 880.0M / US$122.8M) and public filings (Form 20-F) for 2024; PitchBook and company reports give trailing revenue figures (useful for vendor comparisons). RLX is a top branded player in China and expanding internationally.

JUUL Labs — once a market leader in the U.S.; after regulatory/legal setbacks it has returned to FDA review/authorization activity. In July 2025 FDA issued marketing-granted orders allowing JUUL to market several tobacco & menthol JUUL products — a landmark regulatory development. (Altria had previously divested/swapped its Juul stake in 2023.)

Altria Group / NJOY — Altria exited Juul (2023) and subsequently invested in/acquired NJOY (deal announced ~USD 2.75B). Altria later recorded an impairment on its NJOY business (2025 reporting noted a large non-cash impairment). These moves illustrate legacy tobacco firms repositioning in ENDS.

Other big-brand players commonly listed in market reports: Imperial Brands (blu), Japan Tobacco (Logic / Ploom), NJOY (now Altria-owned), NJOY, NJOY, and many regional OEMs/brands in China and SE Asia. Note: most large tobacco groups now report a “smoke-free / new categories / next generation products” line in their FY statements — use those segment lines to compare scale.

Important on “company values”: vendors rarely publish a discrete “vape-only” revenue in free summaries — many figures above are either (a) company segment revenue for “smoke-free / new categories” (PMI/BAT), (b) device-OEM total revenue (Smoore), or (c) transaction values (Altria/NJOY). If you want a clean “vape-only revenue table” I can extract the exact segment lines from each company’s FY/quarterly reports and produce a sourced table (option below).

Recent developments (selected, 2023–mid-2025)
FDA marking activity & regulatory churn: the FDA resumed authorizations under PMTA and in July 2025 granted marketing orders for several JUUL products — a major U.S. regulatory event. At the same time FDA and CBP executed large seizures of unauthorized imported devices in 2025, increasing enforcement.

Big-tobacco repositioning: Altria swapped/returned its JUUL stake (2023), later invested in NJOY (announced ~USD 2.75B), and recorded impairment charges 2025 — signalling strategic reshaping and market risk. PMI and BAT continue to grow “smoke-free / new categories” sales.

OEM consolidation & device supplychains: Smoore and other device makers reported large revenues and continue to dominate device manufacturing for many brand owners.

Market drivers
Adult switching from cigarettes to perceived lower-risk alternatives and growth in smoke-free product shipments (PMI/BAT reporting reflects this).

Product innovation (pods, disposables, improved nicotine salts, device ergonomics) and rising availability of regulated branded products in some markets.

Emerging market expansion (APAC, LATAM) where rising incomes and urbanisation increase demand. Market reports flag APAC as a fast-growing region.

Restraints
Regulatory uncertainty & enforcement (PMTA/marketing orders, flavor restrictions, import seizures) — a major constraint on product availability and growth. FDA actions in 2024–2025 dramatically reshaped the U.S. landscape.

Public-health backlash & litigation — legal settlements and public campaigns affect brand reputations & costs (Juul’s earlier settlements and litigation are an example).

Regional segmentation (high level)
North America (U.S.) — one of the largest markets by spending/ARPU. Market dynamics now strongly shaped by FDA PMTA decisions and enforcement; Mordor/Grand View give different U.S. baseline forecasts depending on scope.

Asia-Pacific (China) — enormous device & brand volumes (RLX, many domestic brands) and large OEM manufacturing (Smoore). Chinese and SE Asian markets drive unit volumes even where per-unit revenue is lower.

Europe — a significant market with established brands (PMI, BAT, Imperial) and growing heated-tobacco / nicotine pouches.

Emerging trends
Shift to regulated, tobacco/menthol approvals in the U.S. (FDA authorizations are selective and reshape retail availability).

Premiumisation & diversification — major tobacco companies pushing higher-margin “smoke-free” portfolios (heat-not-burn, inhalables, oral pouches).

Device OEM concentration — larger OEMs (Smoore) supply multiple brands; vertical integration continues in some regions.

Top use cases
Adult smokers switching to vapes or heated products.

Consumers seeking convenient nicotine delivery (disposables, pods).

Harm-reduction positioning in some markets (industry narrative; controversial in public-health circles).

Major challenges
Enforcement & illicit imports (CBP/FDA seizures 2025) that undercut regulated brands and fuel youth access via unauthorized disposables.

High volatility in brand fortunes (Juul → Altria divestment; NJOY impairment) demonstrates financial risk.

Attractive opportunities
Regulatory-compliant product launches (brands that secure PMTA approval or equivalent in other jurisdictions).

Device OEM partnerships and private-labeling (for regional distributors who want rapid entry without device R&D).

APAC expansion & export from established OEMs — unit growth remains strong in Asia.

Key factors of market expansion
Rate of adult switching from combustible tobacco, regulatory pathways and enforcement, product safety/performance perceived improvements, and continued OEM + brand investment in compliant markets.

Representative sources (pick to inspect)
Grand View Research; Mordor Intelligence; company reports / annual reports (Philip Morris, BAT); Smoore annual results; RLX financial filings; FDA press releases; Reuters / AP / Reuters investor news on Altria/NJOY and enforcement actions.

Want a next step? (I’ll produce it here immediately)
Pick one and I’ll generate it now:

Top-12 companies table with HQ, product focus (device/brand/OEM), and the best available public metric (latest company revenue / “smoke-free” or device segment figure) — I’ll pull the exact segment lines and cite each source.

One-page PPTX summarizing the market snapshot + top vendors slide + a market-size trend chart using the ranges above.

Region deep-dive (USA or China) with region-specific market size estimates, top suppliers, regulatory highlights (FDA/CBP for USA; China market leaders & exports) and source links.

Which of 1, 2 or 3 do you want now?